Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MiMedx Group, Inc.
  6. Summary
    MDXG   US6024961012

MIMEDX GROUP, INC.

(MDXG)
  Report
Delayed Nasdaq  -  04:00:01 2023-01-27 pm EST
3.700 USD   -2.89%
01/09MiMedx Reiterates Q4, 2022 Sales Outlook; Shares Rise
MT
01/09Mimedx Group, Inc. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/09MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
3.5(c) 3.62(c) 3.55(c) 3.81(c) 3.7(c) Last
581 672 682 260 581 605 542 616 529 552 Volume
+2.64% +3.43% -1.93% +7.32% -2.89% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 268 M - -
Net income 2022 -39,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -11,1x
Yield 2022 -
Sales 2023 304 M - -
Net income 2023 -21,0 M - -
Net Debt 2023 - - -
P/E ratio 2023 -20,2x
Yield 2023 -
Capitalization 420 M 420 M -
Capi. / Sales 2022 1,57x
Capi. / Sales 2023 1,38x
Nbr of Employees 811
Free-Float 95,9%
More Financials
Company
MiMedx Group, Inc. is a transformational placental biologics company, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD.... 
Read more
More about the company
Ratings of MiMedx Group, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MIMEDX GROUP, INC.
01/09MiMedx Reiterates Q4, 2022 Sales Outlook; Shares Rise
MT
01/09Mimedx Group, Inc. : Results of Operations and Financial Condition, Regulation FD Disclosu..
AQ
01/09MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on E..
AQ
01/09MiMedx Group, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022
CI
01/05MIMEDX Announces Commercial Launch Of EPIFIX In Japan With Exclusive Distribution Agree..
AQ
01/04MiMedx Signs Distribution Deal with Gunze Medical to Sell EPIFIX in Japan
MT
01/04MiMedx Sings Distribution Deal with Gunze Medical to Sell EPIFIX in Japan
MT
01/04MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agre..
AQ
01/04Mimedx Announces Commercial Launch of Epifix® in Japan with Exclusive Distribution Agre..
CI
01/03Mimedx Group, Inc. : Change in Directors or Principal Officers, Financial Statements and E..
AQ
01/03MiMedx Group Names Ricci Whitlow COO
MT
01/03MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
AQ
01/03MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer
CI
2022Mimedx Group, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2022MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care ..
CI
More news
News in other languages on MIMEDX GROUP, INC.
01/09MiMedx réitère ses prévisions de ventes pour le quatrième trimestre et l'année 2022 ; l..
01/09MiMedx Group, Inc. fournit des prévisions de résultats pour le quatrième trimestre et l..
01/04MiMedx signe un accord de distribution avec Gunze Medical pour vendre EPIFIX au Japon
01/04MiMedx signe un accord de distribution avec Gunze Medical pour vendre EPIFIX au Japon
01/04Mimedx annonce le lancement commercial d'Epifix® au Japon avec un accord de distributio..
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
ETFs positioned on MIMEDX GROUP, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ALPS Medical Breakthroughs ETF - USD0.25%2.47%United_States
IShares Micro-Cap ETF - USD0.09%1.46%United_States
SPDR S&P Biotech ETF - USD0.08%2.76%United_States
Global X S&P Biotech ETF - AUD0.08%0.52%-United_States
Goldman Sachs ActiveBeta U.S. Small Cap Equ...0.06%1.89%United_States
More ETFs positioned on MIMEDX GROUP, INC.
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,70 $
Average target price 10,25 $
Spread / Average Target 177%
EPS Revisions
Managers and Directors
K. Todd Newton Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Ricci S. Whitlow Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.33.09%420
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622